What Is Zepbound (Tirzepatide)? Eli Lilly's Weight Loss Injection Explained

How Zepbound Works: Dual Receptor Activation

Tirzepatide targets two incretin hormone receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual mechanism sets it apart from single-target GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic). GIP receptor activation appears to amplify the weight-lowering and metabolic effects beyond what GLP-1 stimulation achieves alone 1.

The Role of GLP-1

GLP-1 receptor agonism slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves postprandial insulin secretion. These effects have been well-documented since the development of exenatide and liraglutide 2. Patients on GLP-1-based therapies consistently report feeling full sooner and experiencing less food-focused thinking between meals.

Why GIP Matters

GIP was once considered a "pro-obesity" hormone because of its role in fat storage. But preclinical and clinical data now suggest that pharmacologic GIP receptor activation at supraphysiologic doses actually reduces body weight and fat mass 3. The combination of GIP and GLP-1 agonism may also improve lipid metabolism and reduce hepatic fat content more than either pathway alone.

A Single Molecule, Two Targets

Tirzepatide is not a combination of two drugs. It is a single 39-amino-acid peptide engineered with a C20 fatty diacid moiety that extends its half-life to approximately five days, allowing once-weekly dosing 1. This design makes it structurally distinct from every other approved GLP-1 receptor agonist on the market.

SURMOUNT Clinical Trial Results

The Zepbound approval rests primarily on the SURMOUNT trial program, a series of phase 3 randomized controlled trials enrolling thousands of adults with obesity or overweight. The data from these trials represent some of the largest weight reductions ever reported with a pharmacologic agent.

SURMOUNT-1: The Key Trial

Published in the New England Journal of Medicine in 2022, SURMOUNT-1 randomized 2,539 adults without diabetes (BMI ≥30, or ≥27 with a comorbidity) to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo for 72 weeks 4. Mean weight loss results were striking:

• 5 mg: 15.0% body weight reduction
• 10 mg: 19.5% body weight reduction
• 15 mg: 22.5% body weight reduction
• Placebo: 3.1%

More than one-third of participants on the 15 mg dose lost ≥25% of their body weight. By comparison, semaglutide 2.4 mg in the STEP-1 trial (N=1,961) produced 14.9% mean weight loss at 68 weeks 5.

SURMOUNT-2: Obesity With Type 2 Diabetes

SURMOUNT-2 enrolled 938 adults with both obesity and type 2 diabetes, a population that historically loses less weight on anti-obesity medications. Participants on tirzepatide 15 mg lost a mean of 14.7% body weight at 72 weeks, with HbA1c reductions of 2.1 percentage points 6. The placebo group lost 3.2%. These findings confirmed that the dual agonist retains meaningful efficacy even in a metabolically resistant population.

SURMOUNT-3 and SURMOUNT-4

SURMOUNT-3 tested tirzepatide after a 12-week intensive lifestyle intervention lead-in, showing an additional 18.4% weight loss on top of the weight already lost during the lifestyle phase 7. SURMOUNT-4 examined weight regain after drug discontinuation. Participants who stopped tirzepatide after 36 weeks regained approximately half the weight they had lost by week 88, while those who continued treatment maintained or extended their losses 8. This trial reinforced that obesity is a chronic disease requiring ongoing treatment.

FDA-Approved Dosing Schedule

Zepbound uses a structured dose-escalation protocol designed to minimize gastrointestinal side effects. All doses are administered via a single-use, pre-filled auto-injector pen 9.

Titration Steps

The prescribing information specifies:

• Weeks 1 through 4: 2.5 mg once weekly (initiation dose, not a maintenance dose)
• Weeks 5 through 8: 5 mg once weekly
• Increase by 2.5 mg every 4 weeks as tolerated
• Maximum dose: 15 mg once weekly

Clinicians may hold a patient at any tolerated dose rather than pushing to the maximum. The 5 mg, 10 mg, 12.5 mg, and 15 mg doses are all approved as maintenance doses. Dr. Ania Jastreboff, an obesity medicine specialist at Yale who served as lead investigator for SURMOUNT-1, stated: "The dose-response curve with tirzepatide is clear, but clinical judgment should guide how far and how fast to titrate based on the individual patient's tolerability and goals" 4.

Injection Technique

Patients inject Zepbound subcutaneously in the abdomen, thigh, or upper arm. The injection site should be rotated weekly. Each pen is used once and discarded. No reconstitution or mixing is required.

Side Effects and Safety Profile

Gastrointestinal symptoms are the most common adverse events with Zepbound, consistent with the broader GLP-1 receptor agonist class. Most events are mild to moderate and tend to decrease over time, particularly during the early titration phase.

Common Adverse Events

In the SURMOUNT-1 trial, the most frequently reported side effects at the 15 mg dose included 4:

• Nausea: 31% (vs. 9% placebo)
• Diarrhea: 23% (vs. 7% placebo)
• Constipation: 11% (vs. 5% placebo)
• Vomiting: 12% (vs. 2% placebo)
• Injection-site reactions: 7%

Discontinuation due to adverse events occurred in 4.3% to 7.1% of tirzepatide groups versus 2.6% in placebo.

Boxed Warning and Contraindications

The FDA label carries a boxed warning about thyroid C-cell tumors based on rodent studies with GLP-1 receptor agonists 9. This has not been confirmed in humans, but Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should not be used with other tirzepatide-containing products or with any GLP-1 receptor agonist.

Pancreatitis and Gallbladder Events

Acute pancreatitis has been reported. Patients should be monitored for persistent, severe abdominal pain. Cholelithiasis and cholecystitis rates were also higher in the tirzepatide groups than placebo across the SURMOUNT program. Rapid weight loss itself increases gallstone risk regardless of the pharmacologic agent used 10.

Cost, Insurance Coverage, and Access

The sticker price of Zepbound is a barrier for many patients. Eli Lilly set the list price at $1,059.87 for a four-week supply, making it one of the more expensive anti-obesity medications on the market 11.

Insurance Field

Coverage varies widely. Many commercial insurers now cover anti-obesity medications, but prior authorization requirements are common. Employers may exclude weight-management drugs from their formularies. Medicare Part D does not cover anti-obesity medications by statute, although legislative efforts to change this (the Treat and Reduce Obesity Act) remain active.

Lilly's Savings Programs

Eli Lilly offers a commercial savings card that may reduce out-of-pocket costs to as little as $25 per month for eligible commercially insured patients. Patients without insurance coverage can access LillyDirect, a direct-to-patient pharmacy program offering single-dose vials at reduced prices.

Compounded Tirzepatide

During FDA-declared shortages of tirzepatide, 503A and 503B compounding pharmacies produced compounded versions at lower cost. The FDA has taken enforcement actions as the shortage has resolved, and the legal and safety field around compounded tirzepatide continues to shift 9. Patients should discuss sourcing only with licensed prescribers.

Zepbound vs. Wegovy: Key Differences

Both Zepbound (tirzepatide) and Wegovy (semaglutide 2.4 mg) are FDA-approved for chronic weight management, but they differ in mechanism, efficacy data, and pricing.

Efficacy Comparison

No head-to-head randomized trial has been published comparing tirzepatide and semaglutide for weight loss. Cross-trial comparisons suggest a meaningful difference. SURMOUNT-1 reported 22.5% mean weight loss with tirzepatide 15 mg at 72 weeks 4, while STEP-1 reported 14.9% with semaglutide 2.4 mg at 68 weeks 5. Differences in trial design, patient populations, and endpoints limit direct comparison. The SURPASS-2 trial (type 2 diabetes, not obesity-specific) did compare tirzepatide head-to-head with semaglutide 1 mg and found superior HbA1c and weight reductions with tirzepatide 12.

Mechanism

Wegovy activates only the GLP-1 receptor. Zepbound activates both GIP and GLP-1 receptors. Whether the GIP component accounts for the higher weight loss or whether dose-response characteristics explain the gap remains an area of active research.

Side Effect Profile

GI side effects are reported at similar rates in both programs. The American Gastroenterological Association notes that nausea and diarrhea are class effects of incretin-based therapies and should be managed with slow titration, dietary modifications, and temporary dose holds when necessary 13.

Who Is Eligible for Zepbound?

The FDA-approved indication specifies adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea 9.

Prescreening Considerations

Before starting Zepbound, clinicians should assess:

• Thyroid history (rule out personal/family history of MTC or MEN 2)
• Pancreatitis history
• Gallbladder disease
• Current medications, particularly insulin or sulfonylureas (dose adjustments may be necessary to avoid hypoglycemia)
• Pregnancy status (Zepbound is not recommended during pregnancy)

Special Populations

Limited data exist for patients over age 75. Patients with severe gastrointestinal motility disorders, including gastroparesis, may not tolerate incretin-based therapies. No dose adjustment is required for mild to moderate renal or hepatic impairment based on pharmacokinetic analyses 9.

Beyond Weight: Emerging Cardiometabolic Data

Weight loss is the primary endpoint, but tirzepatide's metabolic effects extend further. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity recommends GLP-1 receptor agonists (including dual agonists) as first-line pharmacotherapy when lifestyle intervention is insufficient, noting: "Medications that produce ≥15% weight loss may be preferred when patients have obesity-related complications that benefit from greater weight reduction" 14.

Cardiovascular Outcomes

The SURPASS-CVOT trial is evaluating major adverse cardiovascular events (MACE) with tirzepatide in patients with type 2 diabetes and established cardiovascular disease. Results have not yet been published, but the SELECT trial demonstrated that semaglutide 2.4 mg reduced MACE by 20% over a median 39.8 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) 15. Whether tirzepatide will match or exceed that benefit remains unknown.

Obstructive Sleep Apnea

The SURMOUNT-OSA trial showed that tirzepatide reduced the apnea-hypopnea index (AHI) by approximately 50% in adults with moderate-to-severe obstructive sleep apnea and obesity, leading to an FDA-expanded indication for this population 16. This was the first pharmacologic therapy approved specifically for OSA.

Hepatic Fat Reduction

In SURMOUNT-2, tirzepatide reduced liver fat content measured by MRI-proton density fat fraction. Ongoing trials are investigating tirzepatide's potential role in metabolic dysfunction-associated steatohepatitis (MASH), where weight loss of ≥10% is associated with fibrosis regression 6.

Practical Considerations for Starting Zepbound

Patients initiating Zepbound should expect a gradual dose escalation over 16 to 20 weeks to reach their target maintenance dose. Keeping a food diary, eating slowly, and choosing smaller, protein-rich meals can reduce the severity of GI side effects during titration. Dehydration from nausea and vomiting should be addressed promptly. Patients on insulin or sulfonylureas must coordinate with their prescriber to adjust those doses as weight and glucose levels change. The maintenance dose should be the lowest effective dose that produces clinically meaningful weight loss and symptom improvement, and ongoing treatment is expected for most patients based on the SURMOUNT-4 regain data 8.